[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global In-Silico Drug Discovery Market: Focus on Products, Technologies, Workflow, End Users, Country Data (17 Countries), and Competitive Landscape – Analysis and Forecast, 2018-2029

January 2020 | 159 pages | ID: G17C3B538B5BEN
BIS Research Inc.

US$ 4,250.00 US$ 5,000.00 -15 %
Offer valid until June 30, 2020!

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Key Questions Answered in this Report:
  • What are the major market drivers, challenges, and opportunities in the global in-silico drug discovery market?
  • What are the underlying structures resulting in the emerging trends within the global in-silico drug discovery market?
  • How is each segment of the global in-silico drug discovery market expected to grow during the forecast period and what is the estimated revenue to be generated by each of the segments by the end of 2029?
  • What is the expected compound growth rate to be witnessed by the leading players in the market during the forecast period 2019-2029?
  • What are the key applications in the global in-silico drug discovery market? What are the major segments of these applications?
  • Who are the key manufacturers the global in-silico drug discovery market, and what are their contributions?
Global In-Silico Drug Discovery Market Forecast, 2019-2029

The in-silico drug discovery industry analysis by BIS Research projects the market to grow at a significant CAGR of 12.92% during the forecast period, 2019-2029. The in-silico drug discovery market generated $2,094.5 million revenue in 2018, in terms of value. The global in-silico drug discovery market growth has been primarily attributed to the major drivers in this market such as emphasis on reduction in medical errors and readmission rates, growth in the biomarker identification market and advancements in In-silico drug discovery techniques, and computational technological advancements in the field of computational biology. However, there are significant challenges which are restraining the market growth. These challenges include high cost of methods and expensive procedures and their applications in medical treatments.

Expert Quote

“North America is the leading contributor in the in-silico drug discovery market and contributed approximately 41.65% to the global market value in 2018. This region is anticipated to grow at a significant CAGR during the forecast period 2019-2029 and continue dominating the global market in 2029. However, the Asia-Pacific region is expected to grow at the highest CAGR of 13.29% during the forecast period. In addition, the region of Europe also contributed a significant share of 28.40% to the global market in 2018.”

Scope of the Market Intelligence on the In-Silico Drug Discovery Market

The in-silico drug discovery research provides a holistic view of the market in terms of various factors influencing it, including regulatory reforms, and technological advancements.

The scope of this report is centered upon conducting a detailed study of the products and manufacturers allied with the service market. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, growth potential of each underlying sub-segment, and company, as well as other vital information with respect to global in-silico drug discovery market.

Market Segmentation

The global in-silico drug discovery market segmentation (on the basis of manufacturing and services) is further segmented on the basis of workflow, product, software, end user, and region.

The global in-silico drug discovery market segmentation (on the basis of product) is segmented into software, software as services, and consultancy as a service.

The global in-silico drug discovery market segmentation (on the basis of workflow) is segmented into discovery, pre-clinical tests, and clinical trials.

The global in-silico drug discovery market segmentation (on the basis of software) is segmented into molecular modelling and de novo drug design, and pharmacophore modelling software.

The global in-silico drug discovery market segmentation (on the basis of end user) is segmented into contract research organizations, pharmaceutical industries, and academic and research institutes.

The global in-silico drug discovery market segmentation (on the basis of region) is segmented into North America, Europe, Asia-Pacific, Latin America, and rest-of-the-world.

Key Companies in the In-Silico Drug Discovery Market

The key manufacturers who have been contributing significantly to the global in-silico drug discovery market include Albany Molecular Research Inc., Certara USA, Inc., Charles River, Chemical Computing Group ULC, Collaborative Drug Discovery Inc., Dassault System (Biovia), Evotec A.G., GVK Biosciences Private Limited, ICAGEN, INC., Novo Informatics Pvt. Ltd., Numerate Inc., PerkinElmer Inc, Schr?dinger, LLC, Selvita, Simulation Plus, and WuXi AppTec, among others.
1 PRODUCT DEFINITION

1.1 Inclusion and Exclusion

2 RESEARCH SCOPE

2.1 Scope of the Study
2.2 Key Questions Answered in the Report

3 RESEARCH METHODOLOGY

3.1 Global In-Silico Drug Discovery Market: Research Methodology
3.2 Primary Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model

4 INDUSTRY ANALYSIS

4.1 Regulatory Framework
  4.1.1 Regulatory Framework in North America
  4.1.2 Regulatory Framework in Europe
  4.1.3 Regulatory Framework in Asia-Pacific

5 COMPETITIVE LANDSCAPE

5.1 Mergers and Acquisitions
5.2 Product Launches and Product Updates
5.3 Synergistic Activities
5.4 Business Expansion Activities and Others
5.5 Market Share Analysis

6 MARKET DYNAMICS

6.1 Overview
6.2 Impact Analysis
6.3 Market Drivers
  6.3.1 Emphasis on Reduction in Medical Errors and Readmission Rates
  6.3.2 Growth in the Biomarker Identification Market and Advancements in In-Silico Drug Discovery Techniques
  6.3.3 Technological Advancements in the Field of Computational Biology
6.4 Market Restraints
  6.4.1 Lack of High Complexity Testing Centers
  6.4.2 Expensive Procedures and Their Applications in Medical Treatments
  6.4.3 High Capital Requirement Hampering the Expansion of Global Reach
6.5 Market Opportunities
  6.5.1 Massive Scope for Adoption of In-Silico drug discovery in Developing Nations
  6.5.2 Integration of Blockchain Technology in Interoperability
  6.5.3 Collaborations with Precision Medicine Providers

7 IN-SILICO DRUG DISCOVERY: OVERVIEW

7.1 Introduction
7.2 Market Availability for In-Silico Drug Discovery
7.3 In-Silico Drug Discovery Market Technology Trends

8 GLOBAL IN-SILICO DRUG DISCOVERY MARKET (BY WORKFLOW)

8.1 Overview
8.2 Discovery
  8.2.1 Target Identification
    8.2.1.1 Bioinformatics
    8.2.1.2 Reverse Docking
    8.2.1.3 Protein Structure Prediction
  8.2.2 Target Validation
  8.2.3 Lead Discovery
    8.2.3.1 Library Design
    8.2.3.2 Pharmacophore
8.3 Pre-Clinical Tests
8.4 Clinical Trials

9 GLOBAL IN-SILICO DRUG DISCOVERY MARKET (BY PRODUCT)

9.1 Software
9.2 Software as a Service (Cloud)
9.3 Consultancy as a Service

10 GLOBAL IN-SILICO DRUG DISCOVERY MARKET (BY SOFTWARE TYPE)

10.1 Molecular Modeling and de Novo Drug Design Software
10.2 Pharmacophore Modeling Software

11 GLOBAL IN-SILICO DRUG DISCOVERY MARKET (BY END USER)

11.1 Contract Research Organizations
11.2 Pharmaceutical Industry
11.3 Academic and Research Institutes
11.4 Other End Users (Hospitals and Other Care Facilities)

12 GLOBAL IN-SILICO DRUG DISCOVERY MARKET, BY REGION

12.1 Overview
12.2 North America
  12.2.1 U.S.
  12.2.2 Canada
12.3 Europe
  12.3.1 Germany
  12.3.2 France
  12.3.3 U.K.
  12.3.4 Italy
  12.3.5 Spain
  12.3.6 Russia
  12.3.7 Rest-of-Europe
12.4 Asia-Pacific
  12.4.1 China
  12.4.2 Japan
  12.4.3 Australia
  12.4.4 India
  12.4.5 South Korea
  12.4.6 Rest-of-APAC
12.5 Latin America
  12.5.1 Brazil
  12.5.2 Mexico
12.6 Rest-of-the-World

13 COMPANY PROFILES

13.1 Overview
13.2 Albany Molecular Research Inc.
  13.2.1 Company Overview
  13.2.2 Role of Albany Molecular Research Inc.in the Global In-Silico Drug Discovery Market
  13.2.3 SWOT Analysis
13.3 Certara USA, Inc.
  13.3.1 Company Overview
  13.3.2 Role of Certara USA, Inc. in the Global In-Silico Drug Discovery Market
  13.3.3 SWOT Analysis
13.4 Charles River
  13.4.1 Company Overview
  13.4.2 Role of Charles River in the Global In-Silico Drug Discovery Market
  13.4.3 Financials
  13.4.4 SWOT Analysis
13.5 Chemical Computing Group ULC
  13.5.1 Company Overview
  13.5.2 Role of Chemical Computing Group ULC in the Global In-Silico Drug Discovery Market
  13.5.3 SWOT Analysis
13.6 Collaborative Drug Discovery Inc.
  13.6.1 Company Overview
  13.6.2 Role of Collaborative Drug Discovery Inc., in the Global In-Silico Drug Discovery Market
  13.6.3 SWOT Analysis
13.7 Dassault System (Biovia)
  13.7.1 Company Overview
  13.7.2 Role of Dassault System (Biovia) in the Global In-Silico Drug Discovery Market
  13.7.3 SWOT Analysis
13.8 Evotec A.G.
  13.8.1 Company Overview
  13.8.2 Role of Evotec A.G. Company in the Global In-Silico Drug Discovery Market
  13.8.3 Financials
  13.8.4 Key Insights About Financial Health of the Company
  13.8.5 SWOT Analysis
13.9 GVK Biosciences Private Limited
  13.9.1 Company Overview
  13.9.2 Role of GVK Biosciences Private Limited in the Global In-Silico Drug Discovery Market
  13.9.3 SWOT Analysis
13.10 ICAGEN, INC.
  13.10.1 Company Overview
  13.10.2 Role of ICAGEN, INC. in the Global In-Silico Drug Discovery Market
  13.10.3 Financials
  13.10.4 Key Insights About Financial Health of the Company
  13.10.5 SWOT Analysis
13.11 Novo Informatics Pvt. Ltd.
  13.11.1 Company Overview
  13.11.2 Role of Novo Informatics Pvt. Ltd. in the Global In-Silico Drug Discovery Market
  13.11.3 SWOT Analysis
13.12 Numerate, Inc.
  13.12.1 Company Overview
  13.12.2 Role of Numerate Inc. in the Global In-Silico Drug Discovery Market
  13.12.3 SWOT Analysis
13.13 PerkinElmer, Inc.
  13.13.1 Company Overview
  13.13.2 Role of PerkinElmer Inc, in Global In-Silico Drug Discovery Market
  13.13.3 Financials
  13.13.4 Key Insights About Financial Health of the Company
  13.13.5 SWOT Analysis
13.14 Schr?dinger, LLC
  13.14.1 Company Overview
  13.14.2 Role of Schr?dinger, LLC in the Global In-Silico Drug Discovery Market
  13.14.3 SWOT Analysis
13.15 Selvita
  13.15.1 Company Overview
  13.15.2 Role of Selvita in the Global In-Silico Drug Discovery Market
  13.15.3 SWOT Analysis
13.16 Simulation Plus
  13.16.1 Company Overview
  13.16.2 Role of Simulation Plus in the Global In-Silico Drug Discovery Market
  13.16.3 Financials
  13.16.4 Key Insights About Financial Health of the Company
  13.16.5 SWOT Analysis
13.17 WuXi AppTec
  13.17.1 Company Overview
  13.17.2 Role of WuXi AppTec in the Global In-Silico Drug Discovery Market
  13.17.3 Financials
  13.17.4 Key Insights About Financial Health of the Company
  13.17.5 SWOT Analysis
13.18 e-therapeutics plc (Snapshot)
  13.18.1 Company Overview
  13.18.2 Role of e-therapeutics plc in the Global In-Silico Drug Discovery Market
  13.18.3 Financials

LIST OF TABLES

Table 4.1: Regulatory Framework for In-Silico Drug Discovery Market in North America
Table 4.2: Regulatory Framework for In-Silico Drug Discovery Market in Europe
Table 4.3: Regulatory Framework for In-Silico Drug Discovery Market in Asia-Pacific
Table 6.1: Country-Wise Analysis of Adverse Events, 2016

LIST OF FIGURES

Figure 1: Cost Benefit Analysis between Conventional and In-Silico Method
Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global In-Silico Drug Discovery Market
Figure 3: Global In-Silico Drug Discovery Market, by Workflow, 2018 vs. 2029 ($Million)
Figure 4: Global In-Silico Drug Discovery Market, by Product, 2018 vs. 2029 ($Million)
Figure 5: Global In-Silico Drug Discovery Market, by Software Type, 2018 vs. 2029 ($Million)
Figure 6: Global In-Silico Drug Discovery Market, by End User, 2018 vs. 2029 ($Million)
Figure 7: Global In-Silico Drug Discovery Market Snapshot
Figure 2.1: Global In-Silico Drug Discovery Market Segmentation
Figure 3.1: Global In-Silico Drug Discovery Market Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 5.1: Share of Key Developments and Strategies, January 2016–June 2019
Figure 5.2: Product Launches Share (by Company), January 2016–December 2019
Figure 5.3: Synergistic Activities Share (by Company), January 2016–December 2019
Figure 5.4: Business Expansion Activities Share (by Company), January 2016–December 2019
Figure 5.5: Market Share Analysis for the In-Silico Drug Discovery Market, 2018
Figure 6.1: Impact Analysis
Figure 7.1: Different Steps in the In-Silico Drug Discovery Process
Figure 8.1: Global In-Silico Drug Discovery Market (by Workflow)
Figure 8.2: Global In-Silico Drug Discovery Market (by Workflow), 2018-2029
Figure 8.3: Global In-Silico Drug Discovery Market (Target Identification), 2018-2029
Figure 8.4: Global In-Silico Drug Discovery Market (Bioinformatics), 2018-2029
Figure 8.5: Global In-Silico Drug Discovery Market (Reverse Docking), 2018-2029
Figure 8.6: Global In-Silico Drug Discovery Market (Protein Structure Prediction), 2018-2029
Figure 8.7: Global In-Silico Drug Discovery Market (Target Validation), 2018-2029
Figure 8.8: Global In-Silico Drug Discovery Market (Lead Discovery), 2018-2029
Figure 8.9: Global In-Silico Drug Discovery Market (Library Design), 2018-2029
Figure 8.10: Global In-Silico Drug Discovery Market (Pharmacophore), 2018-2029
Figure 8.11: Global In-Silico Drug Discovery Market (Pre-Clinical Tests), 2018-2029
Figure 8.12: Global In-Silico Drug Discovery Market (Clinical Trials), 2018-2029
Figure 9.1: Global In-Silico Drug Market (Software), 2018-2029
Figure 9.2: Global In-Silico Drug Market (Software as a Service), 2018-2029
Figure 9.3: Global Molecular In-Silico Drug Discovery Market (Consultancy as a Service), 2018-2029
Figure 10.1: Global In-Silico Drug Discovery Market (by Molecular Modeling and de Novo Drug Design Software), 2018-2029
Figure 10.2: Global In-Silico Drug Market (Pharmacophore Modeling Software), 2018-2029
Figure 11.1: Global In-Silico Drug Discovery Market (Contract Research Organizations), 2018-2029
Figure 11.2: Global In-Silico Drug Discovery Market (Pharmaceutical Industry), 2018-2029
Figure 11.3: Global In-Silico Drug Discovery Market (Academic and Research Institutes), 2018-2029
Figure 11.4: Global In-Silico Drug Discovery Market (Hospitals and Other Care Facilities), 2018-2029
Figure 12.1: Global In-Silico Drug Discovery Market (by Region)
Figure 12.2: Global In-Silico Drug Discovery Market (by Region), 2018-2029
Figure 12.3: Global In-Silico Drug Discovery Market Share (by Region), 2018
Figure 12.4: Global In-Silico Drug Discovery Market Share (by Region), 2029
Figure 12.5: North America In-Silico Drug Discovery Market, 2018-2029
Figure 12.6: North America: Market Dynamics
Figure 12.7: North America In-Silico Drug Discovery Market (by Country), 2018-2029
Figure 12.8: U.S. In-Silico Drug Discovery Market, 2018-2029
Figure 12.9: Canada In-Silico Drug Discovery Market, 2018-2029
Figure 12.10: Europe In-Silico Drug Discovery Market, 2018-2029
Figure 12.11: Europe: Market Dynamics
Figure 12.12: Europe In-Silico Drug Discovery Market (by Country), 2018-2029
Figure 12.13: Germany In-Silico Drug Discovery Market, 2018-2029
Figure 12.14: France In-Silico Drug Discovery Market, 2018-2029
Figure 12.15: U.K. In-Silico Drug Discovery Market, 2018-2029
Figure 12.16: Italy In-Silico Drug Discovery Market, 2018-2029
Figure 12.17: Spain In-Silico Drug Discovery Market, 2018-2029
Figure 12.18: Russia In-Silico Drug Discovery Market, 2018-2029
Figure 12.19: Rest-of-Europe In-Silico Drug Discovery Market, 2018-2029
Figure 12.20: Asia-Pacific In-Silico Drug Discovery Market, 2018-2029
Figure 12.21: APAC: Market Dynamics
Figure 12.22: APAC In-Silico Drug Discovery Market (by Country), 2018-2029
Figure 12.23: China In-Silico Drug Discovery Market, 2018-2029
Figure 12.24: Japan In-Silico Drug Discovery Market, 2018-2029
Figure 12.25: Australia In-Silico Drug Discovery Market, 2018-2029
Figure 12.26: India In-Silico Drug Discovery Market, 2018-2029
Figure 12.27: South Korea In-Silico Drug Discovery Market, 2018-2029
Figure 12.28: RoAPAC In-Silico Drug Discovery Market, 2018-2029
Figure 12.29: Latin America In-Silico Drug Discovery Market, 2018-2029
Figure 12.30: Latin America: Market Dynamics
Figure 12.31: Latin America In-Silico Drug Discovery Market (by Country), 2018-2029
Figure 12.32: Brazil In-Silico Drug Discovery Market, 2018-2029
Figure 12.33: Mexico In-Silico Drug Discovery Market, 2018-2029
Figure 12.34: Rest-of-Latin America In-Silico Drug Discovery Market, 2018-2029
Figure 12.35: RoW In-Silico Drug Discovery Market, 2018-2029
Figure 13.1: Total Number of Companies Profiled
Figure 13.2: Albany Molecular Research Inc.: Product Portfolio
Figure 13.3: Albany Molecular Research Inc.: SWOT Analysis
Figure 13.4: Certara USA, Inc.: Product Portfolio
Figure 13.5: Certara USA, Inc.: SWOT Analysis
Figure 13.6: Charles River: Overall Financials, 2016-2018
Figure 13.7: Charles River: Revenue (by Segment), 2016-2018
Figure 13.8: Charles River: SWOT Analysis
Figure 13.9: Chemical Computing Group ULC: Product Portfolio
Figure 13.10: Chemical Computing Group: SWOT Analysis
Figure 13.11: Collaborative Drug Discovery Inc.: Overall Product Portfolio
Figure 13.12: Collaborative Drug Discovery Inc.: SWOT Analysis
Figure 13.13: Dassault Systems (Biovia): Product Offerings
Figure 13.14: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 13.15: Evotec A.G. Company: Overall Financials, 2016-2018
Figure 13.16: Evotec A.G.: R&D Expenditure, 2016-2018
Figure 13.17: Evotec A.G. Company: SWOT Analysis
Figure 13.18: Product Portfolio: GVK Biosciences Private Limited
Figure 13.19: GVK Biosciences Private Limited SE.: SWOT Analysis
Figure 13.20: ICAGEN, INC.: Overall Product Portfolio
Figure 13.21: ICAGEN, INC.: Overall Financials, 2016-2018
Figure 13.22: ICAGEN, INC.: R&D Expenditure, 2016-2018
Figure 13.23: ICAGEN, INC.: SWOT Analysis
Figure 13.24: GE Healthcare: Product Portfolio
Figure 13.25: Novo Informatics Pvt. Ltd. Company: SWOT Analysis
Figure 13.26: Numerate Inc.: Overall Product Portfolio
Figure 13.27: Numerate Inc.: SWOT Analysis
Figure 13.28: PerkinElmer, Inc.: Product Portfolio for Global In-Silico Drug Discovery Market
Figure 13.29: PerkinElmer, Inc.: Overall Financials, 2016-2018
Figure 13.30: PerkinElmer, Inc.: Revenue (by Segment), 2016-2018
Figure 13.31: PerkinElmer, Inc.: Revenue (by Region), 2016-2017
Figure 13.32: PerkinElmer, Inc.: Revenue (by Region), 2018
Figure 13.33: PerkinElmer, Inc.: R&D Expenditure ,2016-2018
Figure 13.34: PerkinElmer, Inc.: SWOT Analysis
Figure 13.35: Schr?dinger, LLC: SWOT Analysis
Figure 13.36: Selvita: Product Portfolio
Figure 13.37: Selvita: SWOT Analysis
Figure 13.38: Simulation Plus: Product Portfolio
Figure 13.39: Simulation Plus.: Overall Financials, 2017-2019
Figure 13.40: Simulation Plus: Revenue (by Region), 2017-2019
Figure 13.41: Simulation Plus: R&D Expenditure, 2016-2018
Figure 13.42: Simulation Plus: SWOT Analysis
Figure 13.43: WuXi AppTec.: Overall Financials, 2017-2019
Figure 13.44: WuXi AppTec: R&D Expenditure, 2016-2018
Figure 13.45: WuXi AppTec: SWOT Analysis
Figure 13.46: e-therapeutics plc: Product Portfolio
Figure 13.47: e-therapeutics plc: Overall Financials, 2017-2019


More Publications